GlobalHealth Threats

15 December: The vaccination campaign for children 6 to 11 years of age began on 14 December, as announced (in Indonesian) by the Ministry of Health. The program was kicked off in three areas; Jakarta, Depok and South Tangerang Cities, and will be gradually rolled out in areas with higher vaccination rates for the elderly and general population first. An additional 26.5 million children will be targeted for vaccination. They will be offered the Sinovac vaccine in two doses, with a 28 day interval.

To date more than 255 million doses have been administered, with over 50% of the population 12 years and older fully vaccinated.

3 November: The Sinovac vaccine has been approved (in Indonesian) for emergency use in children aged 6-11 years, with rollout to this age group expected to start in early 2022. In addition the Novavax vaccine has been granted emergency use authorisation – the first in the world according to the press release from the manufacturer.

The country has been achieving around 1.5 million vaccinations per day in the last fortnight. Over 197 million vaccines have been administered, which equates to over 45% of the population receiving at least one dose, over 27% of the population fully vaccinated and over 77% of healthcare workers having received a third dose with the Moderna vaccine. Boosters for the general population are expected to be rolled out in 2022.

7 October: A tenth COVID-19 vaccine has been given emergency use approval (in Indonesian) by the Indonesian regulatory body, BPOM. Zifivax, developed in Chinese by Anhui Zhifei Longcom Biopharmaceutical, requires three doses over one month. The vaccine as been given to around 4,000 people in Indonesia as part of the global Phase 3 clinical trials. Interim results showed 79.88% vaccine efficacy 14 days after the third dose in Indonesia, with good efficacy against all four Variants of Concern – 77.47% against Delta and 90% or higher for Alpha, Beta and Gamma. PT. Jakarta Biopharmaceutical Industry is currently constructing a vaccine production facility to “fill and finish” materials shipped from China and prepare vials and prefilled syringes for local use.

Over 150 million vaccine doses have been administered, with almost 20% of the total population now fully vaccinated.

21 September: The Johnson & Johnson and Convidecia (made by CanSinoBio) vaccines were granted Emergency Use Authorisation (in Indonesian) by the Indonesian regulatory body on 7 September. They are both single dose vaccines and can be used in people 18 years and older. There are now 9 COVID-19 vaccines approved for use.

Foreigners with a Temporary Stay Visa (KITAS) are now eligible to apply for a COVID-19 vaccine through the government programme.

More than 127 million vaccine doses have been administered. This includes over 22% of the target population over 12 years of age fully vaccinated, and over 58% of all healthcare workers receiving a third vaccine dose.

Additional supplies of Johnson & Johnson, Pfizer/BioNTech, Sinopharm and Sinovac have arrived in the last fortnight.

Vaccinations issued abroad can now be verified for proving vaccination status in Indonesia and using the PeduliLindungi app. The website can be accessed at https://vaksinln.dto.kemkes.go.id/sign/in.

3 September: The Sputnik V vaccine was granted Emergency Use Authorisation by the Indonesian regulatory body on 25 August.

The Moderna vaccine is now available for the first two doses for the public who are unvaccinated and unable to receive Sinovac or Oxford/AstraZeneca vaccines. Priority is being given to people who are immunocompromised. The Pfizer/BioNTech and Sinovac vaccines are being administered to adolescents 12 to 17-years-old across the country.

Over 104 million vaccines doses have been administered; over 31% of the target population over 12 years have had a first dose and 18% are fully vaccinated. Almost half of the 1.46 million healthcare workers have received a third dose. The capital Jakarta and the island of Bali have the highest percentage of their population fully vaccinated at 68% and 52% respectively.

24 August: The first shipment of Pfizer/BioNTech has arrived, containing over 1.56 million doses of a total 50 million doses ordered. The President reports that 370 million doses are already secured for delivery by the end of the year, but more supplies will be needed to meet the target of 200 million people vaccinated by the end of 2021.

Vaccination campaigns are being conducted in schools and door-to-door programmes in East Java. These door-to-door campaigns will be rolled out across the country.

The self-financed vaccine program has been cancelled by the Ministry of Health. Only the public program (using the Sinovac, Oxford/AstraZeneca, Moderna, Pfizer/BioNTech, Sinopharm and Novavax vaccines) and the Gotong Royong Corporate program (using Sinopharm - targeting around 7.5 million adults) will continue in the country.

A private vaccine program for expatriates to receive the Sinopharm vaccine began in Jakarta on 24 August. Registration can be done through https://linktr.ee/vaksinkadinjakarta. Vaccinations will be conducted at the KADIN (Indonesia Chamber of Commerce and Industry) Branch and costs 700,000 IDR for both injections.

More than 90 million doses have been administered. Over 27% of the target population (208 million people) have received the first dose and more than 15% are fully vaccinated. Over 30% of healthcare workers have already received a third booster dose with Moderna.

12 August: Conditional approval has been granted for mRNA vaccines (Moderna and Pfizer/BioNTech) and Sinovac to be used for vaccinating pregnant women in the second trimester.

The Ministry of health has clarified the interval between vaccine doses. For Sinovac, the interval is 28 days, for Oxford/AstraZeneca the interval is 2-3 months, and survivors can be vaccinated 3 months after recovery.

Over 78.5 million vaccine doses have been administered, with 12.5% of the population fully vaccinated.

27 July: Mass vaccine campaigns with Sinovac have been held for children aged 12 to 17 years across the country. Over 746,000 have received a first dose since they became eligible at the start of the month. Since 16 July, Moderna vaccines have been used to give healthcare workers a third vaccine dose to boost immunity.

The self-pay vaccination program which was to be run through Kimia Farma pharmacy clinics has been cancelled.

The Government reports mass vaccination is being conducted at five banks – this covered employees and their families as well as customers of Mandiri, BRI, BNI, BCA, and CIMB Niaga banks. The initial phase targets over 112,000 people in 13 cities. The second phase targets over 31,000 people in 48 cities.

Further shipments of Oxford/AstraZeneca, Sinovac and Sinopharm vaccines have arrived in the last fortnight. Around 45 million Sinovac, Moderna and Pfizer-BioNTech vaccine doses are expected to be received in August.

Over 63.3 million vaccine doses have been administered, with over 18 million people fully vaccinated.

14 July: The Japanese Ministry of Foreign Affairs announced today that nearly 1 million doses of COVID-19 vaccine will be provided to Indonesia. The delivery is expected to arrive on 15 July.

13 July further update: Media reports that the self-pay vaccine program through Kimia Farma has been halted. It will resume again once there is a sufficient supply of vaccinations through the free public program.

Ingredients to make a further 10,000,280 Sinovac vaccines have arrived, taking the total Sinovac vaccines available to over 115 million doses.

13 July: The Moderna vaccine has been granted Emergency Use Authorisation. Over 3 million doses have arrived in the country and will be used to give all healthcare workers a third vaccine dose, in order to boost immunity amid the surge of Delta variant transmission.

On 12 July, a self-pay vaccination option began through Kimia Farma pharmacy clinics, which are State-Owned Enterprises. Eight clinics across six cities will be offering the Sinopharm vaccine, with more clinics and additional vaccines (Moderna and CanSino) expected to become available in the coming months. All adults are eligible, including foreigners who need to provide their passport and residency permit (KITAS / KITAP) to participate. The cost for two doses is 879,140 IDR. Registration is through the Kimia Farma call center #1-500-255, via the website https://kimiafarmaapotek.co.id/ or on the Kimia Farma App (App will be ready from 15 July).

Since 1 July, vulnerable adolescents aged 12 to 17 years in Jakarta have been eligible to be vaccinated with the Sinovac vaccine.

Further shipments from Sinovac of raw ingredients to make 14 million doses of Vaksin COVID-19 have been received. Australia and Japan are also donating over 2 million doses each of the Oxford-AstraZeneca vaccine.

Over 51 million vaccine doses have been administered, with over 15 million people fully vaccinated.

29 June: The President has announced the Indonesian Food and Drug Administration (BPOM) has issued Emergency Use Authorisation for Sinovac to be given to 12 to 17-year-olds. An announcement about when children could start being vaccinated is yet to be made.

The general adult population has been eligible for vaccination across several urban centers in western Java since 19 June, including Jakarta, Bogor, Depok, Tangerang, Bekasi and greater Bandung. Some walk-in appointments may be available at mass vaccination centres, subject to availability on the day.

Disability-friendly mass vaccination centres are being established across the country to open up accessibility for the phase 3 group which includes almost 64 million vulnerable people.

Further shipments of 10 million doses of Sinovac and 1 million doses of Sinopharm vaccines have been received in the last fortnight.

An adjustment to the Corporate Vaccination program (Vaksinasi Gotong Royong) allows for corporations with more than 200 employees to begin organising vaccination campaigns with their own provider. Corporations with less than 200 employees can have campaigns conducted through a Government approved vaccine provider.

More than 41.6 million vaccine doses have been administered to date. The country is aiming to vaccinate 1 million people a day in July and 2 million people per day in August.

19 June: Since 8 June, Phase 3 of the vaccination campaign has been underway. This means around 64 million vulnerable people are now eligible for vaccination. In addition, vaccination has been opened up to everyone aged 18 years and above in Jakarta (in Indonesian). Media reports that younger people who accompany those over 60 years to a vaccination appointment will also be offered vaccines, in a bid to increase uptake in the elderly population.

Further mass vaccination centres have been opened up around the country, with the President tweeting (in Indonesian) his goal is to have 700,000 vaccinations a day in June. This is planned to increase to 1 million vaccinations per day in July.

The Government has addressed the infections of vaccinated healthcare workers. The MOH states 308 healthcare workers in Kudus, Central Java tested positive to COVID-19. This is out of a total of over 5,880 healthcare workers who were fully vaccinated. Most have already recovered and resumed work. “The vaccine given to them is really effective in protecting against the worst conditions,'' states the District Health Office head.

As of 18 June, more than 35 million doses have been administered. For the Phase 1 and 2 campaign, around 100% of 1.5 million healthcare workers and 17 million public servants have received at least one vaccine. Under 20% of the 21.5 million people over 60 years have received one vaccine.

17 June: Concerns rise over the efficacy of some vaccines against the more virulent strains of COVID-19. Media reports more than 350 Indonesian doctors and healthcare workers have contracted COVID-19 despite being vaccinated with Sinovac.

2 June: Phase 3 of the vaccination campaign began on 19 May as a pilot program in Jakarta province. Vulnerable people living in red zones or areas with high levels of transmission are eligible for vaccination in this phase.

Campaigns to encourage elderly people to be vaccinated have been held by the Ministry of Health across Indonesia in the lead up to National Elderly Day on 29 May. Vaccination stations are being set up in villages to reduce the need for elderly people to travel far to health facilities to be vaccinated.

On 27 May, the Ministry of Health cleared the AstraZeneca batch CTMAV-547 for use. Toxicity and sterility testing found no issues. A further 8 million doses of the Sinovac vaccine arrived on 25 May, taking the national stockpile to almost 84 million doses. As of 2 June, over 27.7 million doses have been administered through the public program.

In the first week of operation, the Corporate vaccination program administered over 21,000 doses of the Sinopharm vaccine. These were given to employees from 27 companies across 18 healthcare facilities in Jakarta, West Java, Rau Islands and Maluku provinces.

21 May: The corporate vaccination program (Vaksinasi Gotong Royong) began on 18 May. The program allows for businesses to register their employees and families to receive vaccines outside of the government run program, at nominated private facilities. Registration can be done through the Indonesian Chamber of Commerce and Industry website https://vaksin.kadin.id/.

The employers must pay the cost of vaccination. Over 13 million employees have been registered to date. The government has released 500,000 doses of Sinopharm to be used for the program, initially running across Java.

As of 20 May, over 14.6 million people have received the first vaccine dose through the public vaccination program, with over 9.7 million people fully vaccinated.

16 May: Authorities suspended distribution of a batch of AstraZeneca vaccine to test for sterility and toxicity. A 22-year-old man died a day after immunisation from the "CTMAV547" batch. It contains nearly 450,000 doses and arrived in Indonesia last month from COVAX. Doses have been distributed in Jakarta and the province of North Sulawesi, and given to the military.

1 May: Authorities have granted Emergency Use Authorization for Sinopharm vaccine. It is approved for use in people over 18, and requires 2 doses, 21 to 28 apart. So far, over 480,000 doses have arrived in the country, and a total of 7.5 million doses are planned. The vaccine is to be used in a private immunisation programme in cooperation with the government, known as Gotong Royong, which is expected to roll out later this month. Organisations can purchase the supplies from the government stocks for use in their workforce. Vaccination must be free for employees, and the number of vaccinations must be reported to authorities.

21 April:The vaccination program continues to be rolled out across all 34 provinces. As of 20 April, over 17.2 million vaccine doses have been administered. Of the 1.4 million healthcare workers targeted in Phase 1, 99.4% have received the first vaccine and 90.3% have been fully vaccinated. Of Phase 2, which is being conducted in two parts; 42.6% of the 17 million public servants have received the first dose and 10.5% of the 21.5 million elderly people have has the first dose.

Another shipment containing enough raw materials for 6 million doses of the Sinovac vaccine have arrived. These will be processed by BioFarma and locally distributed under the name “Vaksin Covid-19”.

31 March: Over 10 million vaccine doses have been administered, with over 97.7% of Phase 1 priority group (healthcare workers) and 35.2% of Phase 1 priority group (People over 60 years and public servants) receiving at least the first dose.

20 March: Media is reporting that the AstraZeneca COVID-19 vaccine has been approved for emergency use in the country. Earlier, Indonesia had suspended the use of the vaccine after reports of blood clots in people after getting the vaccine.

19 February: Media reports that people who refuse to be vaccinated against COVID-19 will be denied social assistance or fined (up to 5 million rupiah). A December poll of over 1,200 people reportedly found 37% of people would willingly get vaccinated, 40% were undecided and 17% would refuse.

16 February: Indonesian authorities have granted emergency use authorisation (in Indonesian) to the CoV2BIO / Vaksin COVID-19 vaccine. This vaccine is the Chinese developed Sinovac vaccine that is locally produced by Biofarma. Around 15 million doses are ready to be used, with the second priority group of frontline and public workers to be vaccinated.

The country aims to have 38 million people vaccinated by the end of April 2021.

15 February: The second phase of the vaccination campaign is set to begin across Java and Bali from 17 February, according to media. This would include public servants.

As of 11 February, over 1 million healthcare workers had already been vaccinated. Since 8 February, elderly health workers have been receiving the recently approved Sinovac vaccine.

7 February: Sinovac's Coronavac has been approved (in Indonesian) by the food and drug agency (BPOM) for use in the elderly.

3 February: Raw materials to make an additional 10 million doses have arrived in the country (in Indonesian). Bio Farma will be using these to produce the Sinovac vaccine, which will locally be marketed as CoV2Bio. In addition to the 3 million ready made vaccines from Sinovac already received and previously received raw materials, the country has the capacity to deliver 28 million doses. Raw materials for an additional 20 million doses are pending delivery.

The President’s office has announced (in Indonesian) that more than 500,000 healthcare workers have been vaccinated to date. This is out of a total target population of 1.5 million workers. Following the completion of vaccination of around 1.5 million healthcare workers by the end of February, the next priority group will be 17.4 million public servants aged 18-59 years.

27 January: Second doses of the Sinovac vaccine, called CoronaVac, have begun being administered from today (14 days after the first dose). The President and several politicians and other high profile health staff received their second dose (in Indonesian).

23 January: Vaccination has rolled out across 34 provinces, with healthcare workers the first priority group. Between 14 and 22 January, more than 130,000 people have been vaccinated. The Ulema Council has declared the Sinovac COVID-19 vaccine as halal, and is permissible under Islam.

13 January: The national vaccination campaign has begun, with the President, health minister and other senior government officials receiving their first dose of CoronaVac publicly. The vaccination campaign is expected to take until March 2022 to vaccinate arouns 181.5million people across the country.

11 January: The Indonesian food and drug authority (BPOM) has issued emergency use authorisation (in Indonesian) for the Sinovac COVID-19 vaccine, CoronaVac. This is the first approval for use issued outside of China where the vaccine was developed.

Phase 3 clinical trials conducted in Bandung, West Java, have shown at least 65.3% efficiency in preventing COVID-19 infection. This is however lower than trial results reported in Turkey (91.25% efficiency) and Brazil (78% efficiency). After three months 99.23% of trial participants still had antibodies to COVID-19.

Over 3 million doses of CoronaVac have already been received from China and are being distributed across the country’s 34 provinces. Additional raw materials are set to arrive on 12 January, for the local production of 15 million more vaccines by Bio Farma. The national vaccination campaign is set to begin on 13 January.